Abstract 4228
Background
Lipiodol transcatheter arterial chemoembolization (TACE) , known as c-TACE , is widely used to treat hepatocellular carcinoma (HCC). Recently, a drug-eluting bead (DEB) has been developed to sustain continual drug delivery to the tumor. We evaluate the efficacy and safety of TACE with doxorubicin-loaded drug eluting beads (D-TACE) in this study.
Methods
This retrospective study included 228 unresectable HCC patients who received cTACE (n = 153) or D-TACE(n = 75) in Zhongshan hospital, Fudan University from September 2018 to February 2019. Tumor response were evaluated by MRI according mRECIST one month after treatment, and adverse events were recorded as well.
Results
The disease control rate(DCR) of D-TACE was 78.6% versus 49.3% of c-TACE(p = 0.03),which demonstrated D-TACE had the better tumor reponse. There were no treatment related major complications in all patients, and no statistically significant difference in postembolization syndrome , liver toxicity and hematological toxicity between two groups(p > 0.05). Subgroup analyses indicated that patients with tumor size less than 7cm and tumor numbers less than 3 favored D-TACE , while there was no significant difference in efficacy in the patients with tumor size greater than 10cm (P > 0.05).
Conclusions
In unresectable HCC, transcatheter treatment with DEB loaded with doxorubicin offers a better objective tumor response than conventional TACE, especially in patients with tumor size less than 7cm and tumor numbers less than 3.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4852 - Impact of routine screening and preemptive treatment on hepatitis B virus reactivation (HBVr) in patients receiving chemotherapy
Presenter: Celine Marty
Session: Poster Display session 1
Resources:
Abstract
5225 - The uptake, patient satisfaction and efficacy of scalp cooling among patients receiving chemotherapy in an Irish oncology day ward.
Presenter: William Maher
Session: Poster Display session 1
Resources:
Abstract
1901 - Placebo adverse events (AEs) in targeted and immune cancer therapy in the adjuvant and advanced setting: A systematic review and meta-analysis
Presenter: Diego Enrico
Session: Poster Display session 1
Resources:
Abstract
3258 - Reduced antibody levels and high seronegativity rates against vaccine preventable diseases pose a risk factor for infections in patients with solid and hematologic cancers
Presenter: Angela Guzek
Session: Poster Display session 1
Resources:
Abstract
3211 - Prognostic Factors Influencing Outcome After Therapy With Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin's Lymphoma
Presenter: Veselina Goranova - Marinova
Session: Poster Display session 1
Resources:
Abstract
4949 - Phase I Study of CC-90010 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
Presenter: Victor Moreno
Session: Poster Display session 1
Resources:
Abstract
2271 - Pretreatment coagulation factors related to prognosis in patients with natural killer/T cell lymphoma
Presenter: Yue Chai
Session: Poster Display session 1
Resources:
Abstract
4335 - Diffuse large B cell lymphoma in the elderly. A retrospective analysis of standard versus alternative treatments
Presenter: Irene Sillero
Session: Poster Display session 1
Resources:
Abstract
5117 - MIPI as a superior prognostic tool in Mantle Cell Lymphoma compared to monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratios
Presenter: Filipa Macedo
Session: Poster Display session 1
Resources:
Abstract
5135 - Dose adjustment of chemotherapy in aggressive lymphoma using automated and standardized analysis and evaluation of DNA double strand breaks
Presenter: Julia Schröder
Session: Poster Display session 1
Resources:
Abstract